If approved, subcutaneous autoinjector Leqembi will be the only Alzheimer's medication that can be administered at home. The ...

A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

More than three-quarters of older adults with dementia may be unaware of their diagnosis, a University of Michigan study ...

A new study reveals that over 75% of older adults with dementia may not know they have the disease, with awareness rates even ...

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

Researchers at the University of Michigan found that 80 percent of participants with suspected dementia had not been told ...

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

Treatment with an oral allosteric modulator was nonsuperior to placebo at 6 weeks in a adults with Parkinson’s disease whose ...